Wen Su

Dr. Wen Su

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2020 in Science
Verified
Journal Article
Open access
PDF file
TLThomas W. Linsky
Thomas W. Linsky
RVRenan Vergara
Renan Vergara
NCNuria Codina
Nuria Codina
JNJorgen W. Nelson
Jorgen W. Nelson
MWMatthew J. Walker
Matthew J. Walker
DSDaniel-Adriano Silva
Daniel-Adriano Silva
A decoy to neutralize SARS-CoV-2: Many efforts to develop therapies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are focused on the interaction between the spike protein, which decorates the surface of the virus, and its host receptor, human angiotensin-converting enzyme 2 (hACE2). Linsky et al. describe a de novo design strategy that allowed them to engineer decoy proteins that bind to the spike protein by replicating the hACE2 interface. The best decoy, CTC-445, bound with low nanomolar affinity, and selection of viral mutants that decrease binding is unlikely because this would also affect binding to hACE2. A bivalent version of CTC-445 bound even more tightly, neutralized SARS-CoV-2 infection of cells, and protected hamsters from a SARS-CoV-2 challenge. The stable decoy has the potential for respiratory therapeutic delivery. Science , this issue p. 1208

26 October 2021 in mBio
Verified
Journal Article
Open access
WSWen Su
Wen Su
SSSin Fun Sia
Sin Fun Sia
ASAaron J. Schmitz
Aaron J. Schmitz
TBTraci L. Bricker
Traci L. Bricker
TSTyler N. Starr
Tyler N. Starr
ABAdrianus C. M. Boon
Adrianus C. M. Boon
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein is the main target for neutralizing antibodies. These antibodies can be elicited through immunization or passively transferred as therapeutics in the form of convalescent-phase sera or monoclonal antibodies (MAbs).

1 January 2021 in Emerging Microbes & Infections
Verified
Journal Article
Open access
WSWen Su
Wen Su
SSSin Fun Sia
Sin Fun Sia
KCKa-Tim Choy
Ka-Tim Choy
YJYue Ji
Yue Ji
DCDongdong Chen
Dongdong Chen
HYHui-Ling Yen
Hui-Ling Yen
The segmented genome of influenza A virus has conferred significant evolutionary advantages to this virus through genetic reassortment, a mechanism that facilitates the rapid expansion of viral genetic diversity upon influenza co-infections. Therefore, co-infection of genetically diverse avian influenza viruses in poultry may pose a significant public health risk in generating novel reassortants with increased zoonotic potential. This study investigated the reassortment patterns of a Pearl River Delta-lineage avian influenza A(H7N9) virus and four genetically divergent avian influenza A(H9N2) viruses upon co-infection in embryonated chicken eggs and chickens. To characterize “within-host” and “between-host” genetic diversity, we further monitored the viral genotypes that were subsequently transmitted to contact chickens in serial transmission experiments. We observed that co-infection with A(H7N9) and A(H9N2) viruses may lead to the emergence of novel reassortant viruses in ovo and in chickens, albeit with different reassortment patterns. Novel reassortants detected in donor chickens co-infected with different combinations of the same A(H7N9) virus and different A(H9N2) viruses showed distinct onward transmission potential to contact chickens. Sequential transmission of novel reassortant viruses was only observed in one out of four co-infection combinations. Our results demonstrated different patterns by which influenza viruses may acquire genetic diversity through co-infection in ovo, in vivo, and under sequential transmission conditions.

1 January 2018 in Journal of Infection
Verified
Journal Article
Closed access
WSWen Su
Wen Su
KCKit Ling Cheng
Kit Ling Cheng
DCDaniel K.W. Chu
Daniel K.W. Chu
JZJie Zhou
Jie Zhou
XMXiaoxiao Mao
Xiaoxiao Mao
HYHui-Ling Yen
Hui-Ling Yen

1 January 2019 in Veterinary Record Open
Verified
Journal Article
Open access
PDF file
WSWen Su
Wen Su
RKReimi Kinoshita
Reimi Kinoshita
JGJane Gray
Jane Gray
YJYue Ji
Yue Ji
DYDan Yu
Dan Yu
HYHui-Ling Yen
Hui-Ling Yen
As a unique mammalian host for influenza A viruses, dogs support the transmission of canine influenza viruses (CIVs) of H3N8 and H3N2 subtypes and are susceptible to infection by avian and human influenza viruses. A cross‐sectional serological study was performed to assess the exposure history of dogs in Hong Kong to CIV and human influenza viruses. Among 555 companion dogs sampled in 2015–2017, 1.3 per cent and 9.5 per cent showed hemagglutination inhibition (HI) antibody titre to CIV of H3N8 or H3N2 subtypes and to A(H1N1)pdm09 human influenza viruses, respectively. Among 182 shelter dogs sampled in 2017–2018, none showed HI titre to CIV and 1.1 per cent reacted to H3N2 human influenza virus. There was a poor correlation between ELISA and HI test results. The higher seropositive rates to human influenza viruses suggests that the contact dynamics of dogs under urban settings may affect the exposure risk to human influenza viruses and CIVs.

3 August 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
TLThomas William Linsky
Thomas William Linsky
RVRenan Vergara
Renan Vergara
NCNuria Codina
Nuria Codina
JNJorgen W. Nelson
Jorgen W. Nelson
MWMatthew J. Walker
Matthew J. Walker
DSDaniel-Adriano Silva
Daniel-Adriano Silva
There is an urgent need for the ability to rapidly develop effective countermeasures for emerging biological threats, such as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes the ongoing coronavirus disease 2019 (COVID-19) pandemic. We have developed a generalized computational design strategy to rapidly engineer de novo proteins that precisely recapitulate the protein surface targeted by biological agents, like viruses, to gain entry into cells. The designed proteins act as decoys that block cellular entry and aim to be resilient to viral mutational escape. Using our novel platform, in less than ten weeks, we engineered, validated, and optimized de novo protein decoys of human angiotensin-converting enzyme 2 (hACE2), the membrane-associated protein that SARS-CoV-2 exploits to infect cells. Our optimized designs are hyperstable de novo proteins (∼18-37 kDa), have high affinity for the SARS-CoV-2 receptor binding domain (RBD) and can potently inhibit the virus infection and replication in vitro. Future refinements to our strategy can enable the rapid development of other therapeutic de novo protein decoys, not limited to neutralizing viruses, but to combat any agent that explicitly interacts with cell surface proteins to cause disease.